Obesity

In a woman with a minor risk factor for VTE, transdermal oestrogen should be prescribed in preference to oral oestrogen. This includes women with a raised BMI >30 kg/m2.

Obesity is a risk factor for endometrial hyperplasia or carcinoma and therefore if given HRT they must receive an adequate dose of progestogen. A 52mg levonorgestrel intrauterine device represents the optimal choice.

For more information on when to increase the progestogen dose see prescribing section.